search
Back to results

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Primary Purpose

Cocaine Dependence

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Galantamine
Computer Assisted Cognitive Behavioral Therapy (CBT)
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine Dependence focused on measuring Cocaine, Methadone, CBT

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females between ages of 18 and 50
  • Enrolled in RNP methadone program and stable on methadone for at least 3 weeks
  • Current cocaine abuse or dependence according to DSM-IV criteria
  • No current medical problems and normal ECG
  • If female, not currently pregnant or breast feeding and using reliable birth control
  • Fluent in English and have at least a 6th grade reading level
  • Can commit to 12 weeks of treatment and are willing to be randomized

Exclusion Criteria:

  • Current major psychiatric illness including mood, psychotic or anxiety disorder
  • History of major medical illnesses including asthma, chronic obstructive lung disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances
  • Use of medications including beta blockers and NASAIDs
  • Known allergy to Galantamine

Sites / Locations

  • Kinsella Treatment Center (KTC)
  • Regional Network of Programs

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

Experimental

Experimental

Arm Label

Standard Treatment As Usual (TAU)

TAU Plus Galantamine

TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)

TAU plus CBT plus galantamine

Arm Description

Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.

Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.

TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.

Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.

Outcomes

Primary Outcome Measures

Cocaine Use
Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.
Cocaine Abstinence
operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks

Secondary Outcome Measures

Cognitive Function
A composite using a carefully selected neuropsychological battery that includes measures of executive cognitive functioning frequently affected among cocaine users, likely to be important moderators of CBT4CBT, and sensitive to galantamine effects. These will include measures of multiple aspects of attention, cognitive inhibition, sustained attention (CANTAB), decision making (BART), and memory (digit span). Scores ranged from -1.77 to 1.42 with a higher score indicating higher cognitive functioning.

Full Information

First Posted
December 16, 2008
Last Updated
January 28, 2019
Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00809835
Brief Title
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse
Official Title
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
December 2007 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
We are testing to see if Galantamine, a learning enhancing medication, will help methadone maintained cocaine abusers with their learning and memory specific to CBT using an innovative CBT computer program.
Detailed Description
We are proposing a randomized double blind clinical trial of galantamine and our innovative computer-assisted version of CBT, alone and in combination, to improve treatment outcome and cognitive functioning among cocaine users. The proposed study will be the first to evaluate a cognitive enhancing medication as a means of enhancing the effects of an extremely promising empirically validated behavioral therapy for addiction, and hence bridge cognitive neuroscience and behavioral therapies development. The aim is to conduct a 12 week randomized placebo controlled trial, using a 2x2 factorial model, that will evaluate the efficacy of adding computer assisted training in CBT ("CBT4CBT") and galantamine to standard treatment for 160 cocaine abusing or dependent methadone-maintained individuals. Participants will be randomized to (1) standard treatment (TAU) plus placebo, (2) TAU plus galantamine, (3) TAU plus CBT4CBT plus placebo, or (4) TAU plus CBT4CBT plus galantamine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine Dependence
Keywords
Cocaine, Methadone, CBT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard Treatment As Usual (TAU)
Arm Type
No Intervention
Arm Description
Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
Arm Title
TAU Plus Galantamine
Arm Type
Experimental
Arm Description
Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
Arm Title
TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)
Arm Type
Experimental
Arm Description
TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
Arm Title
TAU plus CBT plus galantamine
Arm Type
Experimental
Arm Description
Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
Intervention Type
Drug
Intervention Name(s)
Galantamine
Other Intervention Name(s)
Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine
Intervention Description
Daily 8 mg galantamine capsule
Intervention Type
Behavioral
Intervention Name(s)
Computer Assisted Cognitive Behavioral Therapy (CBT)
Intervention Description
CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
Primary Outcome Measure Information:
Title
Cocaine Use
Description
Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.
Time Frame
12 weeks
Title
Cocaine Abstinence
Description
operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Cognitive Function
Description
A composite using a carefully selected neuropsychological battery that includes measures of executive cognitive functioning frequently affected among cocaine users, likely to be important moderators of CBT4CBT, and sensitive to galantamine effects. These will include measures of multiple aspects of attention, cognitive inhibition, sustained attention (CANTAB), decision making (BART), and memory (digit span). Scores ranged from -1.77 to 1.42 with a higher score indicating higher cognitive functioning.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females between ages of 18 and 50 Enrolled in RNP methadone program and stable on methadone for at least 3 weeks Current cocaine abuse or dependence according to DSM-IV criteria No current medical problems and normal ECG If female, not currently pregnant or breast feeding and using reliable birth control Fluent in English and have at least a 6th grade reading level Can commit to 12 weeks of treatment and are willing to be randomized Exclusion Criteria: Current major psychiatric illness including mood, psychotic or anxiety disorder History of major medical illnesses including asthma, chronic obstructive lung disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances Use of medications including beta blockers and NASAIDs Known allergy to Galantamine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathleen M Carroll, Ph.D.
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kinsella Treatment Center (KTC)
City
Bridgeport
State/Province
Connecticut
ZIP/Postal Code
06604
Country
United States
Facility Name
Regional Network of Programs
City
Stratford
State/Province
Connecticut
ZIP/Postal Code
06615
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data will be available to other researchers upon request. Please contact Dr. Carroll
Citations:
PubMed Identifier
29286595
Citation
Carroll KM, Nich C, DeVito EE, Shi JM, Sofuoglu M. Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial. J Clin Psychiatry. 2018 Jan/Feb;79(1):17m11669. doi: 10.4088/JCP.17m11669.
Results Reference
derived

Learn more about this trial

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

We'll reach out to this number within 24 hrs